Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada

Mondher Mtibaa,1 Subhajit Gupta,2 Madhusubramanian Muthukumar,2 Jessica Marvel,3 Harneet Kaur,2 Ryotaro Ishikawa,3 Ron Olivenstein4 1Novartis Pharmaceuticals Canada Inc., Dorval, Quebec, Canada; 2Novartis Healthcare Private Limited, Hyderabad, India; 3Novartis Pharma AG, Basel, Switzerland; 4McGill...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Mtibaa M, Gupta S, Muthukumar M, Marvel J, Kaur H, Ishikawa R, Olivenstein R
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	moderate to severe asthma indacaterol acetate glycopyrronium bromide mometasone furoate cost-effectiveness health care payer perspective canada uncontrolled asthma Medicine (General) R5-920 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/2f208fcdacca47f9a9f22c49a8440957
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:2f208fcdacca47f9a9f22c49a8440957
record_format	dspace
spelling	oai:doaj.org-article:2f208fcdacca47f9a9f22c49a84409572021-12-02T19:17:36ZCost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada1178-6981https://doaj.org/article/2f208fcdacca47f9a9f22c49a84409572021-12-01T00:00:00Zhttps://www.dovepress.com/cost-effectiveness-of-once-daily-single-inhaler-indacaterol-acetate-gl-peer-reviewed-fulltext-article-CEORhttps://doaj.org/toc/1178-6981Mondher Mtibaa,1 Subhajit Gupta,2 Madhusubramanian Muthukumar,2 Jessica Marvel,3 Harneet Kaur,2 Ryotaro Ishikawa,3 Ron Olivenstein4 1Novartis Pharmaceuticals Canada Inc., Dorval, Quebec, Canada; 2Novartis Healthcare Private Limited, Hyderabad, India; 3Novartis Pharma AG, Basel, Switzerland; 4McGill University, Montreal, Quebec, CanadaCorrespondence: Mondher MtibaaNovartis Pharmaceuticals Canada Inc., 385 Bouchard Blvd., Dorval, Quebec, H9S 1A9, CanadaTel +1 514 631-6775 ext. 1367Email mondher.mtibaa@novartis.comPurpose: We evaluated the cost-effectiveness of high-dose indacaterol acetate (IND)/glycopyrronium bromide (GLY)/mometasone furoate (MF) (150/50/160 μg, once daily) compared with high-dose salmeterol/fluticasone (SAL/FLU; 50/500 μg, twice daily)+tiotropium (TIO; 5 μg, once daily) (SAL/FLU+TIO) and with high-dose SAL/FLU (50/500 μg, twice daily) for the treatment of inadequately controlled moderate-to-severe asthma.Patients and Methods: A Markov model estimated the incremental cost-effectiveness ratio of treatment with high-dose IND/GLY/MF compared with SAL/FLU+TIO and high-dose IND/GLY/MF compared with SAL/FLU. The model included three health states (day-to-day symptoms without exacerbations, day-to-day symptoms with exacerbations, and death) with a 4-week cycle length. A lifetime time horizon was used. Exacerbation rates and utility values were derived from ARGON and IRIDIUM clinical trials. Canadian dollars (CAD$, 2020) were applied.Results: IND/GLY/MF was the less costly and more effective treatment strategy compared with SAL/FLU+TIO and SAL/FLU in the base-case analyses. IND/GLY/MF had lower costs (CAD $33,501 versus CAD $50,907) and higher quality-adjusted life-years (QALYs) (18.37 versus 18.06 QALYs) compared with SAL/FLU+TIO. Compared with SAL/FLU, IND/GLY/MF had lower costs (CAD $33,408 versus CAD $36,577) and higher QALYs (19.33 versus 19.04 QALYs). IND/GLY/MF was the most cost-effective option in all scenarios tested.Conclusion: IND/GLY/MF was cost-effective at a willingness-to-pay threshold of CAD $50,000/QALY in patients with uncontrolled, moderate-to-severe asthma versus SAL/FLU+TIO and SAL/FLU in the base case and all scenarios tested.Keywords: moderate to severe asthma, indacaterol acetate, glycopyrronium bromide, mometasone furoate, cost-effectiveness, health care payer perspective, Canada, uncontrolled asthmaMtibaa MGupta SMuthukumar MMarvel JKaur HIshikawa ROlivenstein RDove Medical Pressarticlemoderate to severe asthmaindacaterol acetateglycopyrronium bromidemometasone furoatecost-effectivenesshealth care payer perspectivecanadauncontrolled asthmaMedicine (General)R5-920Therapeutics. PharmacologyRM1-950ENClinicoEconomics and Outcomes Research, Vol Volume 13, Pp 957-967 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	moderate to severe asthma indacaterol acetate glycopyrronium bromide mometasone furoate cost-effectiveness health care payer perspective canada uncontrolled asthma Medicine (General) R5-920 Therapeutics. Pharmacology RM1-950
spellingShingle	moderate to severe asthma indacaterol acetate glycopyrronium bromide mometasone furoate cost-effectiveness health care payer perspective canada uncontrolled asthma Medicine (General) R5-920 Therapeutics. Pharmacology RM1-950 Mtibaa M Gupta S Muthukumar M Marvel J Kaur H Ishikawa R Olivenstein R Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada
description	Mondher Mtibaa,1 Subhajit Gupta,2 Madhusubramanian Muthukumar,2 Jessica Marvel,3 Harneet Kaur,2 Ryotaro Ishikawa,3 Ron Olivenstein4 1Novartis Pharmaceuticals Canada Inc., Dorval, Quebec, Canada; 2Novartis Healthcare Private Limited, Hyderabad, India; 3Novartis Pharma AG, Basel, Switzerland; 4McGill University, Montreal, Quebec, CanadaCorrespondence: Mondher MtibaaNovartis Pharmaceuticals Canada Inc., 385 Bouchard Blvd., Dorval, Quebec, H9S 1A9, CanadaTel +1 514 631-6775 ext. 1367Email mondher.mtibaa@novartis.comPurpose: We evaluated the cost-effectiveness of high-dose indacaterol acetate (IND)/glycopyrronium bromide (GLY)/mometasone furoate (MF) (150/50/160 μg, once daily) compared with high-dose salmeterol/fluticasone (SAL/FLU; 50/500 μg, twice daily)+tiotropium (TIO; 5 μg, once daily) (SAL/FLU+TIO) and with high-dose SAL/FLU (50/500 μg, twice daily) for the treatment of inadequately controlled moderate-to-severe asthma.Patients and Methods: A Markov model estimated the incremental cost-effectiveness ratio of treatment with high-dose IND/GLY/MF compared with SAL/FLU+TIO and high-dose IND/GLY/MF compared with SAL/FLU. The model included three health states (day-to-day symptoms without exacerbations, day-to-day symptoms with exacerbations, and death) with a 4-week cycle length. A lifetime time horizon was used. Exacerbation rates and utility values were derived from ARGON and IRIDIUM clinical trials. Canadian dollars (CAD$, 2020) were applied.Results: IND/GLY/MF was the less costly and more effective treatment strategy compared with SAL/FLU+TIO and SAL/FLU in the base-case analyses. IND/GLY/MF had lower costs (CAD $33,501 versus CAD $50,907) and higher quality-adjusted life-years (QALYs) (18.37 versus 18.06 QALYs) compared with SAL/FLU+TIO. Compared with SAL/FLU, IND/GLY/MF had lower costs (CAD $33,408 versus CAD $36,577) and higher QALYs (19.33 versus 19.04 QALYs). IND/GLY/MF was the most cost-effective option in all scenarios tested.Conclusion: IND/GLY/MF was cost-effective at a willingness-to-pay threshold of CAD $50,000/QALY in patients with uncontrolled, moderate-to-severe asthma versus SAL/FLU+TIO and SAL/FLU in the base case and all scenarios tested.Keywords: moderate to severe asthma, indacaterol acetate, glycopyrronium bromide, mometasone furoate, cost-effectiveness, health care payer perspective, Canada, uncontrolled asthma
format	article
author	Mtibaa M Gupta S Muthukumar M Marvel J Kaur H Ishikawa R Olivenstein R
author_facet	Mtibaa M Gupta S Muthukumar M Marvel J Kaur H Ishikawa R Olivenstein R
author_sort	Mtibaa M
title	Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada
title_short	Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada
title_full	Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada
title_fullStr	Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada
title_full_unstemmed	Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada
title_sort	cost-effectiveness of once-daily, single-inhaler indacaterol acetate/ glycopyrronium bromide/ mometasone furoate in patients with uncontrolled moderate-to-severe asthma in canada
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/2f208fcdacca47f9a9f22c49a8440957
work_keys_str_mv	AT mtibaam costeffectivenessofoncedailysingleinhalerindacaterolacetateglycopyrroniumbromidemometasonefuroateinpatientswithuncontrolledmoderatetosevereasthmaincanada AT guptas costeffectivenessofoncedailysingleinhalerindacaterolacetateglycopyrroniumbromidemometasonefuroateinpatientswithuncontrolledmoderatetosevereasthmaincanada AT muthukumarm costeffectivenessofoncedailysingleinhalerindacaterolacetateglycopyrroniumbromidemometasonefuroateinpatientswithuncontrolledmoderatetosevereasthmaincanada AT marvelj costeffectivenessofoncedailysingleinhalerindacaterolacetateglycopyrroniumbromidemometasonefuroateinpatientswithuncontrolledmoderatetosevereasthmaincanada AT kaurh costeffectivenessofoncedailysingleinhalerindacaterolacetateglycopyrroniumbromidemometasonefuroateinpatientswithuncontrolledmoderatetosevereasthmaincanada AT ishikawar costeffectivenessofoncedailysingleinhalerindacaterolacetateglycopyrroniumbromidemometasonefuroateinpatientswithuncontrolledmoderatetosevereasthmaincanada AT olivensteinr costeffectivenessofoncedailysingleinhalerindacaterolacetateglycopyrroniumbromidemometasonefuroateinpatientswithuncontrolledmoderatetosevereasthmaincanada
_version_	1718376904713568256

Cost-Effectiveness of Once-Daily, Single-Inhaler Indacaterol Acetate/ Glycopyrronium Bromide/ Mometasone Furoate in Patients with Uncontrolled Moderate-to-Severe Asthma in Canada

Ejemplares similares